CDC Advises on Limited Nirsevimab Supply and RSV Protection Options
The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Source: infectioncontroltoday.com